Public Reporting

Dr. Roger Cappello

Voting Member and Chair, Lee Davis Medical Associates

Dr. John Kowalski

Dr. Damian Covington

Dr. Paul McTamaney

Voting Member, Medicare Beneficiary Representative

Dr. Dave Taminger

Dr. Steve Young

Dr. Ken Zelenak

Key Clinical and Administrative Leadership

ACO Executive

Dr. Ken Zelenak

Medical Director

Ms. Tiffany Lange

Compliance Official

ACO Committees and Committee Leadership

Quality Committee: Dr. Ken Zelenak, Chair

Managing Committee: Mr. Tom Gallo, Chair

Specialist Mobilization Committee: Dr. Mark Monahan, Co-Chair and Dr. Johnny Wong, Co-Chair

Types of ACO Participants, or Combinations of Participants, that Formed the ACO

Network of individual practices of ACO professionals.

Shared Savings and Losses

Amount of Shared Savings and Losses

Agreement period beginning 2014, Performance Year 1: $0

Agreement period beginning 2014, Performance Year 2015: $0

Agreement period beginning 2014, Performance Year 2016: TBD

How Shared Savings Are Distributed

Proportion invested in infrastructure: Not yet determined

Invested in redesigned care processes/resources: Not yet determined

Proportion of distribution to ACO participants: Not yet determined

Payment Rule Waivers: No, our ACO does not use the SNF 3-Day Rule Waiver.

Quality Performance Results

2015 Reporting Period
Measure NumberMeasure NameACO Performance Rate (%)Mean Performance Rate (SSP ACOs) (%)
ACO-1CAHPS: Getting Timely Care, Appointments, and Information 81.7980.61
ACO-2CAHPS: How Well Your Providers Communicate 92.5092.65
ACO-3CAHPS: Patients’ Rating of Provider 92.4891.94
ACO-4CAHPS: Access to Specialists 83.8683.61
ACO-5CAHPS: Health Promotion and Education57.6559.06
ACO-6CAHPS: Shared Decision Making 70.4875.17
ACO-7CAHPS: Health Status/Functional Status 74.672.3
ACO-34CAHPS: Stewardship of Patient Resources*29.6426.87
ACO-8Risk Standardized, All Condition Readmission13.8914.86
ACO-35Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM)* Readmission16.5418.07
ACO-36All-Cause Unplanned Admissions for Patients with Diabetes*51.4154.60
ACO-37All-Cause Unplanned Admissions for Patients with Heart Failure*65.5876.96
ACO-38All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions58.1762.92
ACO-9Ambulatory Sensitive Condition Admissions: Chronic Obstructive Pulmonary Disease or Asthma in Older Adults (AHRQ Prevention Quality Indicator (PQI) #5)0.661.11
ACO-10Ambulatory Sensitive Conditions Admissions: Heart Failure (AHRQ Prevention Quality Indicator (PQI) #8)1.091.04
ACO-11Percent of PCPs who Successfully Meet Meaningful Use Requirements1.0080.14
ACO-39Documentation of Current Medications in the Medical Record95.3184.07
ACO-13Falls: Screening for Future Fall Risk 87.2056.46
ACO-14Preventive Care and Screening: Influenza Immunization78.3262.03
ACO-15Pneumonia Vaccination Status for Older Adults83.0963.73
ACO-16Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up70.5271.14
ACO-17Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention96.6290.16
ACO-18Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan77.5945.25
ACO-19Colorectal Cancer Screening76.5960.06
ACO-20Breast Cancer Screening78.3765.67
ACO-21Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented 72.0670.04
ACO-40Depression Remission at Twelve Months*0.006.11
ACO-27Diabetes Mellitus: Hemoglobin A1c Poor Control 10.5320.38
ACO-41Diabetes: Eye Exam*57.8941.05
ACO-28Hypertension: Controlling High Blood Pressure 72.8369.62
ACO-30Ischemic Vascular Disease: Use of Aspirin or Another Antithrombotic86.4483.82
ACO-31Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)78.8587.22
ACO-33Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - for patients with CAD and Diabetes or Left Ventricular Systolic Dysfunction (LVEF<40%)77.4377.73
CAHPS = Consumer Assessment of Healthcare Providers and Systems, PQI = Prevention Quality Indicator, LVSD = left ventricular systolic dysfunction, ACE = angiotensin-converting enzyme, ARB = angiotensin receptor blocker, CAD = coronary artery disease.
*= Measure required beginning Reporting Year 2015.
N/A = Reporting on the depression remission measure is not required for 2015, as indicated by N/A.

Click here for 2012-2014 Quality Measure Reporting